Hyper-CVAD Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

The First Affiliated Hospital of Soochow University1
M.D. Anderson Cancer Center1

Indications

Cancer2
B-cell Acute Lymphocytic Leukemia1
Relapsed/Refractory1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1

Other1 trial

Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Phase 2

Houston, Texas1 trial

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.